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NEUROGENESIS IN THE SUBVENTRICULAR ZONE AND HIPPOCAMPUS 
FOLLOWING CELL THERAPY IN A NON-HUMAN PRIMATE MODEL OF 
CORTICAL DAMAGE 
 
LAUREN E. PALITZ 
 
ABSTRACT 
Approximately 795,000 Americans experience a new or recurrent stroke each 
year (American Heart Association 2016; Mozaffarian et al. 2016). However, the only 
experimental therapeutic to have gained FDA approval for treatment of stroke in humans 
is the thrombolytic agent tPA that can dissolve clots and restore blood flow, if given 
within a narrow therapeutic window of a few hours following stroke onset (AHA 2016, 
Li et al. 2016). Nevertheless, in many cases with or without tPA there is significant 
residual impairment, and there are currently no FDA approved therapeutic agents that 
facilitate functional recovery following stroke (Zhang L et al. 2012). Recent studies have 
suggested that neural plasticity and neurogenesis following stroke may play a role in 
recovery of function, and promising findings have been demonstrated with cell therapies 
for enhancing recovery after stroke (Kokaia and Darasalia, 2015; Kozorovitskiy et al, 
2013; Zhao et al, 2012). Our recent study (Moore et al. 2013) showed significant 
recovery of function following a reproducible ischemic lesion limited to the hand 
representation of the motor cortex in non-human primates (NHPs) treated with the 
investigational cell drug product CNTO 0007, that contains human umbilical tissue-
  vii 
derived cells (hUTC). While the treatment group in this study demonstrated significantly 
better recovery of motor function, the mechanism of recovery remains unclear. Previous 
studies conducted with brain tissue from these monkeys have suggested that functional 
recovery may be related to cortical reorganization induced by the hUTC treatment. To 
explore the possibility that neurogenesis may have also played a role in the enhanced 
recovery, these same monkeys received an injection of the thymidine analog 
Bromodeoxyuridine (BrdU), which was visualized in the brain tissue to investigate cell 
proliferation in the subventricular zone and hippocampus. Results show that there is no 
significant difference in the number of BrdU positive cells in the hUTC treated vs. 
untreated monkeys, however there is a trend towards significant increase in BrdU 
labeling in the granule cell layer of the hippocampus of the hUTC treated animals. 
Clusters of proliferating cells were also found in the GCL of treated monkeys, but not in 
the untreated monkeys. These findings support the hypothesis that enhanced recovery of 
function may be related to a combination of reorganization of undamaged cortical motor 
regions and generation of new cells in the brain. 
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 1 
INTRODUCTION 
 
On average, every 40 seconds someone in the United States has a stroke, and the 
number of incident strokes is expected to more than double over the next 40 years 
(American Heart Association, 2016). Stroke is a leading cause of serious long-term 
disability in the United States (Mozaffarian et al., 2015; Murray et al, 2013; CDC, 2012; 
US Census Bureau, 2010), in part due to the substantial motor dysfunction that can 
develop as a result (Arene and Hidler, 2015; Chen et al., 2013). Seventy percent of 
people with stroke experience arm weakness, and up to 66% of these patients do not 
show any recovery in upper limb function at 6 months after stroke (Kwakkel et al, 2015; 
Allison et al, 2009). The recovery of useful hand function after stroke is a major clinical 
challenge for such individuals with moderate to severe paresis, yet critical for returning to 
activities of daily living (McCombe et al, 2014; Cordo et al, 2013). 
Despite a projected 20.5% increase in prevalence of people ≥18 years having a 
stroke by the year 2030 (AHA 2016, Ovbiagele et al, 2013), there continue to be few 
scientifically validated therapeutic techniques with evidence for improvement in motor 
function after stroke (Butler et al, 2006). Currently, the only FDA-approved treatment for 
ischemic stroke is intravenous tissue plasminogen activator (tPA), an anti-thrombotic 
agent that is injected into the bloodstream and acts to dissolve the thrombus and improve 
blood flow to the damaged region (AHA 2016; Li W et al, 2016; Wang et al, 2004; Zivin 
et al, 1985). However, this treatment is only effective if given within the first three to 
four-and-a-half (in eligible patients) hours following damage (AHA 2016; Ebinger et al, 
2015). The median delay time from onset of symptoms to hospital admission is 16 hours 
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(AHA 2016; Zerwic, Hwang, & Tucco, 2007), well past the recommended window for 
tPA administration, and in 2009, administrative data found that only between 3.4% and 
5.2% of acute ischemic strokes were treated with tPA (AHA 2016; Adeoye et al. 2011). 
For this reason, new treatments are needed to facilitate recovery of function following the 
irreversible cortical damage that can occur due to stroke or other traumatic injuries. 
While promising treatments have emerged in rodent models of stroke, attempts to 
translate these treatments to humans have been largely unsuccessful (O’Collins et al, 
2006). 
Following the recommendation of the Stroke Therapy Academic Industry 
Roundtable (STAIR) report recommending that promising therapies be tested in 
gyrencephalic species, such as monkeys, prior to human trials (Fisher et al, 2009), we 
created a rhesus monkey model of reproducible cortical injury (Moore et al, 2012, 2013). 
In this model, we assessed the potential of a cell therapy product (CNTO 0007) to 
facilitate recovery of function following cortical damage. CNTO 0007 contains human 
umbilical tissue-derived cells (hUTC) in a proprietary thaw and inject formulation called 
CSCV4 (Advanced Technologies and Regenerative Medicine, LLC, merged with Depuy 
Orthopaedics, Inc. on 30 December 2012 – Johnson & Johnson). Previous studies 
indicated that hUTC secrete several neurotrophic factors such as brain-derived 
neurotrophic factor (BDNF), fibroblast growth factor 2 (FGF-2), and interleukin 6, all of 
which have the capacity to govern neurorestoration (Zhang et al, 2011; Islam et al, 2009; 
Gorski et al, 2003; Matsuoka et al, 2003; Ferrer et al, 2001). In our study, results 
demonstrated that monkeys who received intravenous administration of the hUTC 
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treatment twenty-four hours following damage to the hand area of the primary motor 
cortex significantly improved fine motor function of the impaired hand compared to 
monkeys that received a placebo solution (Moore et al., 2013). The effect of this 
enhanced recovery of function was most prominent in the first 14 days after surgery. 
Furthermore, the mean time to retrieve a food reward on our motor task was significantly 
different between groups, with the treated group showing a shorter time to retrieve the 
reward across the 12-week post-operative assessment. There was also a significant 
improvement in finger-thumb grasp rating in the monkeys receiving the hUTC treatment 
across this same post-operative period. Despite these striking findings, the 
neuroanatomical changes underlying the recovery remain unknown. 
The loss of motor function that occurs following focal brain injury in the motor 
cortex is caused by cell death resulting from the compromised blood flow to the region; 
specifically, the death of neurons projecting to the corticospinal tract (CST) (Ward and 
Cohen, 2004). Brain plasticity, defined as the brain’s capacity to continuously change its 
structure, and ultimately its function, in response to a stimulus (Kolb 2013), is crucial for 
recovering the function lost due to the death of these neurons via establishing new 
connections within the CST (Teasell et al, 2015; Johansson, 2008; Nudo et al, 2006; 
Ward and Cohen 2004). In response to injury, the brain naturally undergoes remodeling 
with induction of angiogenesis, neurogenesis, and synaptogenesis (Kozorovitskiy et al, 
2013; Zhao et al, 2012; Zhang L et al, 2011; Chopp and Li, 2008). Neuroimaging studies 
in stroke patients have also indicated altered post-stroke activation patterns, which 
suggest some functional reorganization following injury (Johansson 2008; Hallett, 1999; 
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Xerri et al, 1998).  These observations suggest that the damaged brain responds to injury 
by both generating new neurons and reorganizing surviving structures and networks to 
expand their function to include the role of the damaged cells (Johansson, 2008; Nudo et 
al, 2006; Ward and Cohen, 2004). However, these remodeling processes are often 
insufficient in themselves to promote substantial recovery in many patients (Chopp and 
Li, 2008). We hypothesized that the more significant recovery of function observed in 
monkeys treated with hUTC could be due to enhancement of endogenous remodeling and 
restorative brain plasticity processes.    
Specifically, in this study we investigated whether the hUTC treatment may have 
caused amplification of endogenous neurogenesis in the dentate gyrus (DG) of the 
hippocampus and the SVZ in the brains of the treated animals, as suggested by Chopp 
and colleagues (Ryu et al, 2016; Zhang and Chopp, 2009; Chopp and Li, 2008; Mahmood 
et al, 2004). The process of adult neurogenesis encompasses the proliferation of resident 
neural stem and progenitor cells and their subsequent differentiation, migration, and 
functional integration into pre-existing circuitry (Ehninger 2008). During the last decade, 
ischemic insults have been shown to stimulate the formation of new neurons in the adult 
rodent brain from neural stem/progenitor cells located in two regions: the subventricular 
zone (SVZ), lining the lateral ventricle, and the subgranular zone of the granular cell 
layer (SGZ) in the dentate gyrus of the hippocampus (Lindvall et al, 2015). The newly 
generated neurons that result can migrate to areas of ischemic injury, where they may 
have the capacity to enhance brain recovery (Greenberg, 2007; Jin et al, 2006). 
Neurogenesis has been associated with an increase in both cognitive and motor function 
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(Sahay et al., 2011; Creer et al, 2010; Zhao C et al., 2001; Van Praag 2008; 
Kempermann, 2004; Kleim et al, 2003), which may suggest that an increase in 
neurogenesis following injury could help explain the improvements observed in the 
treated animals. Reestablishment of even only a fraction of damaged neuronal circuitries 
could have important clinical implications (Lindvall et al, 2015). 
Neurogenesis is initiated with neural progenitor cell proliferation after stroke, and 
is often therefore measured using thymidine analog labeling as a marker for cell 
proliferation (Kuhn et al 2016, Zhang et al 2007). 5-bromo-2’-deoxyuridine (BrdU) is a 
common, easily detected thymidine analog that has been used in many studies to indicate 
potential neurogenesis in both the dentate gyrus and subventricular zone (Kuhn et al 
2016; Ming and Song 2005). Accordingly, this study quantified the number of BrdU-
incorporating cells in these two regions as a means for detecting neurogenesis following 
hUTC treatment or placebo.  Here we report the post-mortem analysis of the quantity of 
BrdU-positive cells in the dentate gyrus and subventricular zone of the hUTC treated and 
untreated subjects. 
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MATERIALS AND METHODS 
 
Subjects 
This study utilized fixed tissue from eight healthy adult male rhesus monkeys 
(Macaca mulatta), ranging between 5 and 10 years of age (the approximate equivalent to 
a human age ranging from 15-30 years. Tigges et al., 1988), from our previous study 
investigating hUTC treatment (Moore et. al., 2013). All monkeys were obtained from 
either the Caribbean Primate Research Center (Cayo Santiago, Humacao, Puerto Rico) or 
Yerkes National Primate Research Center (Atlanta, GA, USA) and were housed in a 12-
hour light-dark cycle with food and water ad libitum in the Laboratory Animal Science 
Center of Boston University Medical Center, which is accredited by the Association for 
the Assessment and Accreditation of Laboratory Animal Care and staffed by licensed 
veterinarians and trained primate care staff. All procedures were approved by the Boston 
University IACUC and followed NIH guidelines. 
Table 1: All Subjects  
Table 1 lists all subjects that were used in this study. Animals in the “Treated” 
group received the hUTC treatment, while animals in the “Control” group received a 
placebo solution. CPRC indicates that the animals were obtained from the Caribbean 
Primate Research Center (Cayo Santiago, Humacao, Puerto Rico), and Yerkes indicates 
that the animal was obtained from Yerkes National Primate Research Center (Atlanta, 
GA, USA). The age is given in years, with each year representing the equivalent of 
approximately three human years (Tigges et al., 1988). 
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Table 1: All Subjects 
Animal ID Group Age (years) Weight Origin Dominant Hand 
SMO 17j Treated 6.0 8.9 kg CPRC Right 
SMO 21j Treated 8.9 7.8 kg CPRC Left 
SMO 16j Treated 7.6 7.9 kg CPRC Right 
SMO 24j Treated 9.6 15.8 kg Yerkes Right 
SMO 20j Control 6.7 8.2 kg CPRC Left 
SMO 14j Control 5.9 9.3 kg CPRC Right 
SMO 18j Control 6.9 8.0 kg CPRC Right 
SMO 22j Control 8.1 10.0 kg CPRC Left 
Baseline Assessment of Fine Motor Function and Hand Preference 
As previously described (Moore et al, 2010, 2012, 2013), prior to lesion 
placement monkeys were pre-trained on a hand dexterity test (HDT) that is a modified 
version of a Kluver board (Kluver 1935) for a total of 15 days (3 days a week for 5 
weeks). A total of 32 trials were administered each day and equally divided between each 
hand, alternating pseudorandomly. The HDT required animals to precisely manipulate 
their first two digits into opposition in order to retrieve food rewards from two small 1cm 
deep wells of different diameters (25mm and 18mm). The clear apparatus containing the 
wells restricted retrieval to a single hand, and the time it took the monkeys to retrieve the 
food reward was measured by photocells and automatically recorded. A human tester 
monitored all trials and recorded the success or failure of food retrieval.  
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Hand preference was determined following the HDT trials by utilizing “free 
choice” trials that allowed animals to access food rewards in both sides of the apparatus. 
These trials, in addition to an assessment of the acquisition rates for each hand, were used 
to define the “dominant” hand for each animal (Table 1). All trials were videotaped. 
Surgical Model of Cortical Damage 
As previously reported (Moore et al, 2012, 2013), a craniotomy was performed to 
expose the precentral gyrus in the hemisphere controlling the dominant hand. This was to 
ensure that monkeys would be motivated to use the impaired hand during post-operative 
testing despite impairment. 
Once exposed, electrical stimulation was gently applied to the surface of the pia 
through a small, monopolar, silver ball electrode to determine specific foci from which 
the lowest threshold hand movements controlling the finger, thumb, and wrist could be 
elicited. The electrode was moved in rows systematically from dorsal to ventral, and all 
corresponding responses were transcribed onto a calibrated photograph of the region 
(Figure 1A). This photographic “map” was then used as a guide to create a lesion limited 
to the hand representation of the motor cortex (Figure 1B). 
The lesion was created by making a small incision in the pia at the dorsal limit of 
the hand representation area and then inserting a small glass suction pipette under the pia 
to bluntly dissect the small penetrating arterioles as they enter the underlying cortex. This 
approach eliminated the blood supply to the region of interest, but did not directly 
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damage cortical gray matter, resulting in an ischemic lesion of the grey matter with 
preservation of the underlying white matter (Moore et al, 2013). The surgeon who placed 
the lesion was blind to cell therapy condition, and as previously reported (Moore et al, 
2013), there was no group difference in lesion volume between treated and placebo 
monkeys. 
Figure 1: Electrophysiological Map and Anatomical Location of Motor Cortex 
Lesion 
  
Figure 1A shows the electrophysiological map created intraoperatively immediately 
prior to lesion placement. Each dot represents a point of stimulation. Black dots represent 
regions that elicited a fine motor response in the hand, while white dots represent areas 
with no fine motor responses of the hand. Figure 1B shows the resulting lateral view of 
the lesion created intraoperatively from the electrophysiological map shown in Figure 
1A.  
A 
 
B 
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Cell Therapy and Post-Operative Assessment of Fine Motor Function 
hUTC treatment was administered between 23 and 24 hours following lesion 
placement. Cells were removed from liquid nitrogen storage, thawed, and assessed for 
viability. They were then sterilely administered intravenously at a concentration of 10 
million cells/kg at a rate of 0.5 ml/min using a syringe pump. The control animals 
received a placebo solution that was administered at the same volume and rate. The staff 
administering the solution was kept blind to cell therapy condition. 
Post-operative testing began two weeks after surgery and was conducted three 
days a week for 12 weeks. 70% of trials required use of the impaired hand, while 30% 
were administered to the unimpaired hand. The forced use of the impaired hand mimics 
constraint-induced therapy in human rehabilitation strategies (Dobkin 2004). Three hours 
prior to the onset of perfusion-fixation of the brain, monkeys were tested on the HDT one 
last time for one hour. 100% of the trials during this last testing session were given to the 
impaired hand. All trials were videotaped, and the behavioral testing staff were kept blind 
to cell therapy condition. 
A licensed occupational therapist specializing in upper extremity following stroke 
(Dr. Monica Pessina) analyzed the videotapes of the pre- and post-operative HDT results 
using our grasp assessment scale for non-human primates (Moore et al., 2012). This scale 
was adapted from the Eshkol-Wachman Movement Notation (Whishaw et al., 2002; Carr 
et al., 1985) and the Fugl-Meyer Motor Assessment Scale (Fugl-Meyer et al., 1975), and 
consists of hierarchical categories ranging from 0 (no movement) to 8 (normal grasp). 
Each stage includes distinctive features of grasp, such as the shape of the hand and digits 
 11 
during the grasping motion and the pattern of grasp and release, providing a semi-
quantitative measure of grasp function. 
Table 2: Modified Grasp Assessment Scale for Non-Human Primates (Abridged 
version from Moore et al, 2013). 
Table 2: Modified Grasp Assessment Scale for Non-Human Primates (Abridged 
version from Moore et al, 2013). 
0.0 Complete absence of active finger movement and makes no attempt to use 
impaired UE to test. 
1.0 Attempts to use impaired UE to retrieve food reward but no flexion and 
extension of digits either singly or as a group. Unsuccessful at retrieving any 
food rewards. 
2.0 Flexion and extension of digits as a group using less than 15 degrees of digit 
MP flexion. No evidence of the purposeful “scooping” of reward. No 
movement of thumb towards palm. Unsuccessful at retrieving any food 
rewards. 
3.0 Flexion and extension of digits as a group using less than 15 degrees of digit 
MP flexion. Evidence of the development of compensatory “scooping” 
movement of reward toward palm of hand with multiple fingers and mass 
action of digits. Successful retrieval of food reward on at least 10% of trials. 
No movement of thumb towards palm. 
4.0 Flexion and extension of digits as a group using greater than 15 degrees of 
digit MP flexion. Performs purposeful compensatory “scooping” movement of 
reward toward palm of hand with multiple fingers and mass action of digits. 
Successful retrieval of food reward on at least 25% of trials. No movement of 
thumb towards palm. 
5.0 Flexion and extension of digits as a group using greater than 15 degrees of 
digit MP flexion. Performs purposeful compensatory “scooping” movement of 
reward toward palm of hand with multiple fingers and mass action of digits. 
Slight movement of thumb towards palm with a web space no greater than one-
digit width. Thumb does not reach opposition. Successful retrieval of food 
reward on at least 75% of trials. 
6.0 Reaches toward reward with all digits in extension with evidence of isolated 
individual finer movement on at least 10% of trials per day. Mass movement of 
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digits still predominates. The compensatory “scooping” movement toward 
palm is used. Successful retrieval of food reward on at least 75% of trials. 
7.0 Reaches toward reward with all digits in extension with evidence of isolated 
individual digit movement on 50 % of trials per day. The compensatory 
“scooping” movement toward palm is used though becoming less frequent. 
Successful retrieval of food reward on 100% of trials. 
8.0 Pre-operative movement pattern of all digits and hand with no evidence of 
compensatory “scooping” movements. Functional pinch occurs between the 
thumb and 1 individual digit, usually the index finger. 
 
Figure 2: Comparison of Post-Perfusion Lesion on a Gross Scale (Adapted from 
Moore et al. 2013) 
 
Figure 2 shows a lateral view of the lesions in the post-mortem brains of a control animal 
(A) and a treated animal (B), with the treated animal demonstrating greater healing in the 
lesion area. 
A B 
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BrdU Administration 
BrdU was administered to the subjects in a single intraperitoneal injection at a 
dose of 200mg/kg, prepared from a 15 mg/ml solution made in warm, sterile Tris-
buffered saline at pH 7.4. Each monkey had the BrdU solution injected eight days after 
lesion placement. BrdU survival time ranged from 92 to 138 days. One subject, Animal 
ID SMO 24j, had a BrdU survival time of 438 days and was excluded from this study. 
Table 3: BrdU Injection Volumes and Survival Time 
Table 3: BrdU Injection Volumes and Survival Time 
Animal ID Group Injection Volume Survival Time  
17j Treated 130mg/kg 99 days 
21j Treated 115mg/kg 111 days 
16j Treated 130mg/kg 116 days 
24j Treated 241mg/kg 438 days 
20j Control 115mg/kg 106 days 
14j Control 130mg/kg 110 days 
18j Control 120mg/kg 92 days 
22j Control 150mg/kg 138 days 
 
Perfusion and Tissue Processing 
For Perfusion, animals were deeply anesthetized with sodium pentobarbital and 
then killed by exsanguination during transcardial perfusion of the brain using cold Krebs-
Heinsleit buffer (4°C, pH 7.4) followed immediately by fixation with 8 L of warm 4% 
paraformaldehyde (30°C, pH 7.4). The brain was blocked, in situ, in the coronal plane to 
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ensure reproducible planes of section during later processing. It was then removed from 
the skull, weighed, and post-fixed overnight in 4% paraformaldehyde. Following this, it 
was transferred to cryoprotectant solution to eliminate freezing artifact (Rosene et al., 
1986). Cryoprotected blocks were flash frozen at -75°C and stored at -80°C until they 
were cut on a microtome into interrupted series of coronal sections (eight series of 30 μm 
thick sections and one 60 μm thick series) with 300 μm spacing between sections within a 
series. The 60 μm series was immediately mounted on microscope slides and stained with 
thionin for lesion reconstruction. The other series were collected in phosphate buffer with 
15% glycerol and stored at -80°’C. 
BrdU Immunohistochemistry 
A series of every 20th section spaced at 600 μm throughout the entirety of the 
hippocampus and subventricular zone from 8 monkeys was removed from freezer storage 
and thawed to room temperature, then batch-processed together and in the same reagents 
for BrdU according to the following steps: 
First, sections were rinsed 3 times for 5 minutes in 0.05M Potassium Phosphate-
Buffered Saline (KPBS) to remove the glycerol. For antigen retrieval, sections were 
incubated at 65º C for 2 hours in 50% formamide in 2x SSC, followed by three 5-minute 
washes in 2x SSC. Sections were then incubated in 2N HCl for 30 minutes at 37º C to 
create single-stranded DNA and to expose the incorporated BrdU, then rinsed in a 0.1M 
Borate buffer (pH 8.5) for 10 minutes to neutralize the HCl. Sections were washed 2 
times for 5 minutes each in KPBS, then placed in SuperBlock (Thermo Fisher Scientific, 
Waltham, MA) for 30 minutes. After blocking, 1-2 sections per animal were placed into 
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separate wells to serve as negative controls, and were run in parallel from this point 
forward without any primary antibody. All remaining sections were incubated in the 
primary antibody solution containing rat anti-BrdU IgG (1:500; Accurate Chemical & 
Scientific Corporation, Westbury, NY) and 0.4% Triton-X in KPBS buffer for one hour 
at room temperature, followed by 48 hours at 4ºC with gentle agitation. Following this 
period, the sections were washed 3 times for 5 minutes each in KPBS, then incubated for 
1 hour at room temperature in a solution containing biotinylated goat anti-rat secondary 
antibody (1:600; Vector Laboratories, Burlingame, CA) and 0.4% Triton-X in KPBS 
buffer. The sections were washed five times for 5 minutes each in KPBS, incubated in an 
avidin-biotin peroxidase complex (Vector Elite Kit; Vector Laboratories, Burlingame, 
CA) for 1 hour, then rinsed again in KPBS three times for 5 minutes each. 
For visualization, all sections were incubated together for 8 minutes in KPBS 
containing 0.55mM 3-3’-disminobenzidine (DAB; Sigma, St. Louis, MO), and 0.03% 
H2O2, followed by 3 washes for 5 minutes each in KPBS. Free floating sections were 
mounted on gelatin-coated slides and air dried. Sections were then lightly counterstained 
with a 0.05% thionin solution at pH 5.5, dehydrated through a graded series of alcohols, 
cleared with xylene, and coverslipped using Permount mounting medium (Thermo Fisher 
Scientific, Waltham, MA). 
 
Stereological estimation of total number of BrdU+ Cells 
Labeled cells were identified using a 60x oil immersion objective on a Nikon 
E600 series microscope (Nikon; Melville, NY, USA) equipped with a motorized stage 
and StereoInvestigator software (MicroBrightField; Williston, VT, USA). The two 
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regions of interest studied were the subventricular zone of the lateral ventricle and the 
dentate gyrus of the hippocampus. For the subventricular zone, the region of interest was 
restricted to the frontal and anterior parietal lobes and included an area extending 2500 
µm above the most inferior portion of the ventricle. Cells were counted in an area 250 µm 
thick, beginning at the ependymal layer bordering the lumen of the ventricles and 
extending distally (Figure 3). The dentate gyrus was defined as the region of interest 
including a combined molecular layer, granule cell layer (GCL), and hilus (Figure 4). 
Labeled cells were only counted if more than one-third of the nucleus was darkly labeled 
and if the labeled nucleus did not belong to a cell within a blood vessel. This counting 
method omitted lightly labeled cells and endothelial cells from the count. Cells were 
counted throughout the rostral-caudal extent of the GCL. Both hemispheres were 
analyzed for all sections, with ipsilesional and contralesional sides noted. 
Because BrdU-immunostained (BrdU+) cells are relatively rare, accurate 
estimates of numbers required use of an exhaustive sampling scheme. The estimated total 
number of cells was obtained for both subventricular zone and hippocampal sections with 
the operator blind to subject grouping. The cell density was calculated by dividing the 
numbers of BrdU-immunoreactive cells by the area of the ROI. Numbers (N) were 
calculated using the optical fractionator where N = Q x 1/asf x 1/ssf x 1/tsf, as in West et 
al. (1991).      
Figure 3: Outlined Regions of Interest for Stereological Evaluation of SVZ BrdU+ 
Cells.  
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Figure 3 shows the region of interest for the subventricular zone, which was restricted to 
the frontal and anterior parietal lobes and included an area extending 2500 µm above the 
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most inferior portion of the ventricle. Cells were counted in an area 250 µm thick, 
beginning at the ependymal layer bordering the lumen of the ventricles and extending 
distally. Representative schematics (A, C, E, G) and photomicrographs (B, D, F, H) from 
rostral to caudal DAB and thionin stained sections are shown. Scale bar = 1 mm.  
Figure 4: Outlined Regions of Interest for Stereological Evaluation of Hippocampal 
BrdU+ Cells (Adapted from Ngwenya et al 2015).   
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The entire rostral-caudal extent of the hippocampus was evaluated. Representative 
schematics (A, C, E, G) and photomicrographs (B, D, F, H) from rostral to caudal thionin 
stained sections are shown. Scale bar = 1 mm. The granule cell layer (GCL), molecular 
layer (ML), and hilus of the DG were the three components analyzed together and are 
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what we collectively refer to as “the dentate gyrus” throughout this paper. For 
consistency of ROI, the hilus was defined as that area in between the blades of the 
granule cell layer. 
Statistical Analysis 
The data were analyzed using the Statistical Package for Social Sciences software 
(SPSS, version 19.0, Chicago, Ill., USA). A one-way ANOVA was used with the 
treatment group (treated vs. placebo) as the dependent variable. Post hoc tests were 
conducted using the Bonferroni correction for multiple comparisons in order to control 
Type I error at 0.05 for all comparisons.   
All data are presented as means ± SEM unless otherwise noted. Alpha was set at 
0.05. 
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RESULTS 
 
 
Summary of Results 
To examine whether administration of hUTC enhanced hippocampal and SVZ 
cell proliferation, BrdU-incorporating hippocampal and SVZ cells were labeled at 8 days 
post-lesion. Results showed the hUTC treated animals exhibited a trend toward an 
increase in the density of BrdU-positive cells in the GCL of the hippocampus compared 
to controls (p=0.09), but no significant difference was observed in the subventricular 
zone surrounding the lateral ventricles. Clusters of proliferating cells were also found in 
the GCL of treated animals that were not found in the untreated. Animal SMO 24j was 
not used in the statistical analysis of the results shown below due to his untimely BrdU 
injection. 
Effect of hUTC on Concentration of Proliferating Cells into Clusters 
           Interestingly, cells were regularly found in distinct, concentrated clusters in the 
treated animals. Labeling in the untreated animals was more dispersed throughout the 
GCL, and large clusters of labeled cells were not observed in the controls. 
Figure 5: BrdU+ Cell Clustering in hUTC Treated vs. Untreated Monkeys 
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Figure 5 shows an example of an observed cluster of BrdU+ cells in the subgranular zone 
of one of the hUTC treated animals. 5A was taken at a 4x objective. 5B is a zoomed in 
view of the red box seen in 5A, and was taken at a 20x objective. 
Effect of hUTC on Cell Proliferation in the Dentate Gyrus of the Hippocampus 
The results of the one-way ANOVA revealed that monkeys treated with hUTC 
exhibited a trend toward an increase in the density of BrdU-positive cells in the granule 
cell layer in the dentate gyrus of the hippocampus compared with the control monkeys 
(p=0.09). Within group analysis revealed no significant difference in the density or total 
cell estimates of BrdU+ cells in the ipsilesional vs. contralesional hemispheres of both the 
treated and control groups. 
Figure 6: Mean BrdU+ Cell Density (Cells/mm3) and Total Estimated Cell Count in 
the GCL of hUTC Treated vs. Untreated Animals  
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Figure 6 graphically represents the calculated means for the density of BrdU+ cells in 
units of cells/mm3 (6A) and the means of the total estimated number of cells counted in 
the GCL (6B). The black bars represented the hUTC treated group (n=3) and the white 
bars represent the untreated, placebo group (n=4). This figure shows results for each 
hemisphere, with ipsilateral representing the same hemisphere as the lesion. Results 
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demonstrated a trend in the cell density and total estimated cell count in the GCL 
(p=0.09) and no main effect of  hemisphere. 
Table 4: Hippocampal BrdU+ Total Cell Counts and Density Estimates 
Table 4 lists the total cell counts in both the GCL and the dentate gyrus as a whole 
(ML+Hilus+GCL) for each animal as estimated by StereoInvestigator software. In 
addition, the estimated density of BrdU+ cells for each animal was calculated by dividing 
the number of estimated cells by the calculated volume of each region. The mean total 
estimated cell count and cell density estimate for each group (hUTC treated vs. untreated) 
was also calculated and can be viewed below. Animal SMO 24j was excluded from 
analysis due to BrdU injection timing. 
Hippocampal BrdU+ Total Cell Counts and Density Estimates 
   Dentate Gyrus (ML, 
Hilus, and GCL) 
GCL Only 
Animal ID Group Hemisphere Total 
Estimated 
Cell Count 
Density 
(cells/mm3) 
Total 
Estimated 
Cell Count 
Density 
(cells/mm3) 
SMO 21j Treated Ipsilesional 5690.95 120.87 3960.49 267.47 
SMO 21j Treated Contralesional 5153.32 134.34 3699.05 372.29 
SMO 17j Treated Ipsilesional 5146.79 91.85 2702.98 397.36 
SMO 17j Treated Contralesional 5382.26 97.27 2687.73 498.32 
SMO 16j Treated Ipsilesional 8742.86 175.63 5120.89 740.77 
SMO 16j Treated Contralesional 10219.31 191.63 5814.21 829.96 
SMO 24j Treated Ipsilesional 7267.43 85.34 1847.77 369.95 
SMO 24j Treated Contralesional 7683.3 74.57 2585.77 339.03 
Mean 
(excluding 
SMO 24j) 
Treated Ipsilesional 6526.87 117.61 3928.12 502.7 
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Mean 
(excluding 
SMO 24j) 
Treated Contralesional 6919.3 121.16 4067 555.77 
SMO 22j Placebo Ipsilesional 6840.15 106.07 2709.81 276.58 
SMO 22j Placebo Contralesional 6773.15 89.42 3084.55 355.13 
SMO 18j Placebo Ipsilesional 4649.12 95.96 2469.33 259.59 
SMO 18j Placebo Contralesional 4142.75 90.94 2620.89 229.48 
SMO 14j Placebo Ipsilesional 6497.6 88.23 2123.65 279.93 
SMO 14j Placebo Contralesional 6080.64 82.53 1817.1 309.83 
SMO 20j Placebo Ipsilesional 5386.75 96.74 1441.25 203.58 
SMO 20j Placebo Contralesional 4984.2 91.83 1644.94 274.61 
Mean Placebo Ipsilesional 5843.41 96.75 2186.01 245.92 
Mean Placebo Contralesional 5495.19 88.68 2291.87 292.26 
 
Effect of hUTC on Cell Proliferation in the Subventricular Zone of the Lateral 
Ventricles  
The one-way ANOVA revealed no main effect of hUTC treatment between 
groups, and the within group analysis revealed no main effect of hemisphere in the 
subventricular zone of these monkeys. 
Figure 7: Mean BrdU+ Cell Density (Cells/mm3) and Total Cell Counts in SVZ of 
hUTC Treated vs. Untreated Animals 
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Figure 7 graphically represents the calculated means for the density of BrdU+ cells in 
units of cells/mm^3 (7A) and the means of the total estimated number of cells counted in 
the subventricular zone (7B). The black bars represented the hUTC treated group (n=3) 
and the white bars represent the unreated, placebo group (n=4). This figure shows results 
for each hemisphere, with ipsilateral representing the same hemisphere as the lesion. 
Results demonstrated no main effect of treatment or hemisphere in the SVZ for both 
density and total cell estimates.  
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Table 5: BrdU+ and Density Estimates in the SVZ of hUTC Treated and Untreated 
Animals 
Table 5 lists the total cell counts in the SVZ for each animal as estimated by 
StereoInvestigator software. In addition, the estimated density of BrdU+ cells for each 
animal was calculated by dividing the number of estimated cells by the calculated volume 
of each region. The mean total estimated cell count and cell density estimate for each 
group (hUTC treated vs. untreated) was also calculated and can be viewed below. Animal 
SMO 24j was excluded from analysis due to BrdU injection timing. 
SVZ BrdU+ Total Cell Counts and Density Estimates 
Animal ID Group Hemisphere Total Estimated Cell 
Count 
Density 
(cells/mm^3) 
SMO 21j Treated Ipsilesional 15218.67 1004.12 
SMO 21j Treated Contralesional 21230.01 1412.17 
SMO 17j Treated Ipsilesional 3416.99 180.51 
SMO 17j Treated Contralesional 3225.93 188.03 
SMO 16j Treated Ipsilesional 8995.43 627.25 
SMO 16j Treated Contralesional 6663.8 423.52 
SMO 24j Treated Ipsilesional 3077.3 202.73 
SMO 24j Treated Contralesional 4337.41 237.14 
Mean (excluding SMO 
24j) 
Treated Ipsilesional 9210.363 603.97 
Mean (excluding SMO 
24j)  
Treated Contralesional 10373.25 674.57 
SMO 22j Placebo Ipsilesional 6791.2 549.13 
SMO 22j Placebo Contralesional 6388.4 592.19 
SMO 18j Placebo Ipsilesional 6467.6 502.45 
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SMO 18j Placebo Contralesional 3024 229.78 
SMO 14j Placebo Ipsilesional 4488.4 294.23 
SMO 14j Placebo Contralesional 2518 166.93 
SMO 20j Placebo Ipsilesional 7202 567.24 
SMO 20j Placebo Contralesional 4104.4 309.32 
Mean Placebo Ipsilesional 6237.3 478.26 
Mean Placebo Contralesional 4008.7 324.55 
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DISCUSSION 
Summary of Results 
The primary finding of the present study was a trend toward increased cell 
proliferation in the granule cell layer of the hippocampus of monkeys that received hUTC 
cell therapy compared to placebo controls (Figure 6). In addition, BrdU+ cells were 
found in distinct, congregated clusters in the GCL in the treated animals (Figure 5). This 
suggests an increase in cell proliferation in the hUTC treated animals compared to the 
controls, and that increasing endogenous neurogenesis following injury may be mediated 
by hUTC. In addition, the observation of proliferating cells congregating into clusters in 
the GCL of treated animals may provide further evidence that release of trophic factors is 
the primary mechanism by which hUTC acts to enhance recovery of function. 
BrdU as a Marker for Neurogenesis 
 5-bromo-2’-deoxyuridine (BrdU) labeling is a benchmark technique used for 
studying adult neurogenesis in situ (Taupin, 2007). BrdU is an easily detected thymidine 
analog that incorporates into DNA of dividing cells during the S-phase of the cell cycle 
(Taupin 2007) and is therefore used to indicate neurogenesis by measuring cell 
proliferation in the dentate gyrus and the SVZ, two neurogenic sites in the brain where 
neuronal progenitor cells are known to divide. (Kuhn et al 2016; Taupin 2007; Ming and 
Song 2005; Kee et al 2002; Eriksson 1998). The proportion of neural progenitors that 
remain in and exit from the cell cycle determines the degree of neurogenesis (Zhang L et 
al. 2007). 
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BrdU crosses the blood brain barrier (BBB), and it may be delivered by 
intracerebroventricular (i.c.v.), intraperitoneal, or intravenous injection, or orally for 
studying adult neurogenesis. Since i.c.v. injection requires an additional surgery and oral 
delivery poses a challenge in controlling the amount of BrdU absorbed per animal (Kuhn 
et al., 1996, Gould et al., 2001 and Kornack and Rakic, 2001a; Zhao et al., 2003), we 
gave a single intraperitoneal injection of BrdU in our study.  
Hayes and Nowakowski (2002) estimated the length of the cell cycle to 12–14 h, 
and the S-phase corresponds to an estimated third to half of the cell cycle length 
(Takahashi et al., 1995;Alexiades and Cepko, 1996). A single injection of BrdU labels 
nuclei of cells that are in S-phase, but not nuclei of proliferating cells that are in other 
phases of the cell cycle. However, BrdU is only able to effectively incorporate into cells 
for approximately 2 hours following systemic injection  (Packard et al., 1973 and Hayes 
and Nowakowski, 2000), meaning that labeling the total proliferating cell population 
would have required multiple injections of BrdU to incorporate the entirety of S-phase 
(Nowakowski et al., 1989). Although it cannot be assumed that our results represent the 
entire proliferating cell population, our findings and other data suggests that a single 
injection still provides a good estimate of the number of proliferating cells in the brain at 
the time of injection, which was 8 days post-stroke in this study (Taupin 2007).  
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Neurogenesis and Brain Plasticity in the SGZ and SVZ Following Stroke 
Spontaneous recovery of function following stroke involves a combination of 
functional cell plasticity and reorganization including axonal growth, spine remodeling, 
spine activation, activation of cell repair, and neuroanatomical plasticity leading to the 
formation of new connections (Minger et al., 2007; Wieloch and Nikolich 2006).  
Previous studies have demonstrated an increase in neurogenesis, synaptogenesis, and 
angiogenesis following ischemic insult, further promoting the idea that a combination of 
plastic remodeling processes contribute to successful recovery following injury (Zhang et 
al 2011; Wieloch and Nikolich 2006).  
During the last decade, it has been demonstrated that ischemic insults stimulate 
the formation of new neurons in the adult rodent brain from neural progenitor cells 
located in two regions: the subventricular zone (SVZ), lining the lateral ventricle, and the 
subgranular zone (SGZ) of the granular cell layer in the dentate gyrus of the hippocampus 
(Lindvall et al, 2015; Zhang L et al, 2013; Zhang L et al 2011; Anderson 2001; Gates et 
al 1995; Arvidsson et al., 2001; Minger et al., 2007; Jin et al., 2006). These neurons are 
continuously generated up to four months after injury, providing a pool of cells that could 
potentially develop into mature neurons and facilitate recovery (Thored et al., 2006). It 
has been demonstrated that stroke signals for a long distance migration of these resulting 
newly differentiated neurons through several different CNS tissue compartments to 
regions of damage after injury (Carmichael 2010; Arvidsson et al., 2002, Parent et al., 
2002, Zhang et al., 2004 and Ohab et al., 2006), indicating their role in neuroanatomical 
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plasticity and their potential ability to contribute to functional recovery following stroke 
(Greenberg, 2007; Jin et al, 2006; Wieloch and Nikolich 2006).  
This study demonstrated that treatment with hUTC increased the number of 
BrdU-incorporating cells in the GCL of the dentate gyrus, and though the findings were 
not statistically significant, they are consistent with the results of similar studies 
completed by our colleagues with a rodent model of stroke (Zhang L et al., 2013; Zhang 
et al 2011, Chopp et al., 2009). This suggests that hUTC treatment likely promotes the 
endogenous proliferation and maturation of new neurons, enhancing the capacity of the 
brain to recover following injury (Arvidsson et al, 2002; Parent et al., 2002; Greenberg, 
2007; Jin et al, 2006).  
While these results indicate that increasing neurogenesis is likely one of the 
mechanisms in which hUTC therapy acts to enhance recovery of motor function 
following a stroke, it is unlikely that this is the only or even the primary action of the 
hUTC treatment.  It is difficult to imagine how a small number of functional new neurons 
could dramatically enhance functional recovery of cortico–spinal pathways, and it is 
unknown whether these neurons are functionally integrating themselves into the damaged 
CST circuit to replace damaged or dead cells (Burda and Sofroniew, 2014). Newly 
generated neurons are slow to integrate and correctly connect to a target, and early 
recovery often occurs too fast for this to be the cause (Wieloch and Nikolich 2006). It 
appears more likely that neuronal, glial and endothelial progenitor cells supply factors 
that support adaptive remodeling of surviving neurons and neural networks (Zhang et al., 
2005; Lu et al., 2003; Wieloch and Nikolich 2006). Further studies are needed to 
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determine the exact way in which newly proliferating neural progenitor cells act to 
enhance recovery in the damaged brain. 
Release of Trophic Factors as an Underlying Mechanism Following hUTC Therapy 
Human mesenchymal stem cells (hMSCs) derived from human umbilical cord 
tissue have the ability to generate many cell types in vitro, including neurons and glia (Fu 
et al., 2004; Mitchell et al., 2003). These cells can transdifferentiate into neurons in 
experimental neurodegenerative diseases (Koh et al., 2008). However, we speculate that 
the proliferating cells observed in the treated animals of this study are unlikely to be the 
hUTCs themselves. Rather, we believe they are endogenous stem cells present in the 
GCL and SVZ that are upregulated by neurotrophic factors released by the hUTCs into 
the blood. It is more likely that these trophic factors, rather than the cells themselves, 
crossed the BBB. By stimulating neural stem cells to differentiate and proliferate, it is 
viable that the trophic factors contributed to cortical reorganization in response to stroke 
(Chen X et al., 2002; Chopp 2002; Hess 2008). This is based on previous studies 
investigating hUTC therapy for stroke in rats that have reached similar conclusions, and 
have shown that administration of hMSCs increased neurotrophic factor expression, 
which in turn is known to augment host brain plasticity (Zhang et al 2011; Li et al., 
2002). These same studies have also demonstrated that few human cells were detected in 
the ischemic brain 2 months after intravenous administration of hUTC treatment, 
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suggesting that cells were eliminated from the body over time (Zhang et al, 2011; Xiao et 
al., 2005; Cho et al., 2008; Weiss et al., 2006; Koh et al., 2008). This indicates that 
although exogenous cells have the potential to differentiate into parenchymal cells, the 
fact that they are so scarcely found in the brain after treatment suggests that the 
restorative effects of hUTC following stroke are unlikely mediated by direct 
incorporation of these cells into the neural architecture of the host brain (Zhang et al 
2011). 
Clustering of Cells in the Subgranular Zone of the Dentate Gyrus 
 Distinct clusters of cells were observed in the GCL region of the dentate gyrus in 
treated monkeys. Such clusters were rarely, if ever, observed in the control monkeys, and 
their significance has yet to be determined. There are two hypotheses to explain the 
clustering of cells. First, the proliferating cells observed are in fact neural progenitor 
cells, or second, the primary mechanism of the hUTC treatment was indeed a release of 
trophic factors into the bloodstream, which in turn made their way across the BBB to 
stimulate plastic processes. 
Chamaa et al. (2016) noted an increase in BrdU+ labeling congregated into 
clusters in the dentate gyrus following thalamic stimulation in rats, and concluded that 
increased proliferation of BrdU positive cells that appeared as clusters or chains 
suggested a neural stem/progenitor identity (Chamaa et al. 2016; Palmer et al., 2000). 
Given that endothelium, neurons, and glia all arise from the same proliferative focus, this 
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is important as it helps support that the observed BrdU labeled cells are indeed likely to 
be neuronal progenitor cells and not other kinds of proliferating cells (Palmer et al 2000).  
Palmer et al (2000) also observed tight clustering in the dentate gyrus when 
examining neurogenesis in rats, and demonstrated that the area represented by the 
clusters was composed of a mix of neural precursors and cells immunoreactive for 
endothelial markers. However, he noted that the endothelial markers disappeared within a 
few weeks, suggesting that vascular niches provide neural instructive cues and 
corecruitment of these two types of cells (Palmer et al., 2000). If these clusters do indeed 
represent co-stimulation of endothelial cells and neural stem cells, they may provide 
further evidence of a release of trophic factors as the primary mechanism behind hUTC 
therapy. For example, there is an overlap in signaling for the proliferation of both kinds 
of cells from factors such as brain-derived neurotrophic factor (BDNF) and basic 
fibroblast growth factor (FGF-2). BDNF plays a role in promoting both endothelial cells 
and neural precursors, encouraging the survival and differentiation of neuronal precursors 
isolated from rodent proliferative zones, and fostering survival of endothelial cells 
(Donovan et al., 2000; Palmer et al., 2000; Leventhal et al., 1999).  In addition to BDNF, 
FGF-2 is known as both a strong angiogenic factor and strong mitogen for neural stem 
cells in vitro (Kilpatrick and Bartlett, 1995; Gage et al., 1995; Gritti et al., 1996; Palmer 
et al., 1997; Ciccolini and Svendsen, 1998). Peripheral injections of FGF-2 are also able 
to stimulate neurogenesis within the neonatal hippocampal SGZ (Tao et al., 1996; 
Wagner et al., 1999). BDNF and FGF-2 have also both been shown to have the capacity 
to induce neurogenesis, angiogenesis, and synaptogenesis after stroke (Zhang et al 2011; 
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Maric et al., 2007; Schabitz et al., 2004), and our colleagues performing similar studies in 
rats have shown that hUTC secrete both BDNF and FGF-2 among other factors (Zhang et 
al., 2013, Li et al., 2002; Lund et al., 2007, Patterson et al., 1996; Tyler and Pozzo-Miller, 
2001), which further indicates that the above clustering appears to support the release of 
these and other such factors as the primary mechanism in which hUTC is able to 
stimulate brain repair (Zhang et al 2011).  
The overlap in mitogenic function extends to several other growth factors as well. 
For example, VEGF and endothelin are two other angiogenic factors that have been 
shown to be up-regulated in the brain after ischemic or physical injury (Kuwaki et al., 
1997; Liu et el., 1998; Krum and Rosenstein, 1998, 1999; Cobbs et al., 1998; Lee et al., 
1999). Heightened endothelial signaling might, in turn, provide better trophic support for 
newly generated neurons, leading to an increase in the number of new neurons surviving 
long-term. In fact, angiogenic factors such as VEGF may themselves act as trophic 
factors for immature neurons (Sondell et al., 1999). Therefore, it will be important to 
examine angiogenesis in these animals as well to determine whether upregulation also 
occurred in endothelial cells.  
Technical Considerations 
The small number of subjects is the most significant limitation of this study. 
Furthermore, one of the monkeys had a BrdU survival time that was almost four times 
that of the other animals, resulting from the fact that his BrdU administration was given 
well before his lesion placement. For this reason, the counts from this monkey was 
excluded from the data analysis. This made our n even smaller, which may explain the 
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lack of significance calculated from the observed cells. With a higher n, it is likely that 
the difference in the number of BrdU+ cells would have demonstrated significance. 
In addition, BrdU+ only labels cell proliferation, not neurogenesis specifically. 
Although the location of the proliferating cells in neurogenic zones suggests their neural 
progenitor identity, since we did not double label the tissue with a neuronal marker, it is 
impossible to know exactly how many of the proliferating cells were actually neurons. 
Furthermore, this BrdU labeling methodology did not detect neuronal differentiation at 
later stages, so the ultimate fate of these cells remains unknown. Therefore, the specific 
effect of hUTC on neuronal differentiation cannot be definitively stated at this time, and 
our data should be interpreted with caution. 
Implications & Future Directions 
 The most important implication of this study is that growth-factor mediated 
therapy may eventually provide a viable avenue for recovery of function in human 
patients. Since promising hUTC treatments in rats have now been shown to be effective 
in NHPs, this may be a favorable future option for clinical trials in human stroke patients.  
An important future direction will be to examine the degree to which cortical 
reorganization and plasticity is affected by stem cell therapy, and the specific 
mechanisms in which it acts. In addition, exploring the role of inflammation following 
stroke could also provide key insight into the mechanisms of the therapy. Similar studies 
are also needed in more aged monkeys to determine the difference in which the aged 
brain responds to hUTC administration when compared to younger models.  
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 Further studies are also needed to identify the types of BrdU+ cells that appear in 
the observed clusters. In addition, angiogenesis, apoptosis, synaptic plasticity, and 
dendritic remodeling need to be investigated in this tissue. 
Conclusion 
The major finding of the current study is an increase in cell proliferation in the 
dentate gyrus of monkeys treated with hUTC. These findings are consistent with the work 
of Chopp, Zhang and colleagues (Zhang L et al., 2013; Zhang et al 2011, Chopp et al., 
2009), who performed similar studies in rats. Therefore, it can be hypothesized that the 
cell therapy enhanced and facilitated the neurogenesis in the dentate gyrus and SVZ of 
the treated animals, and that this may contribute to recovery of function in response to 
ischemic damage. 
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o Presented at 2012, 2013 Convention on student leadership and programming 
• Experimental Biology National Conference 
o Over 14,000 in attendance 
o Held at the Boston Convention and Exhibition Center 
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o Attended sessions on medical education, research in teaching, and poster 
sessions 
 
MEMBERSHIP AFFILIATIONS 
 American Association of Anatomists 
 Student Osteopathic Medical Association 
 American Medical Student Association 
 
OTHER SKILLS 
 Language: Elementary proficiency in Spanish, can read and write Hebrew 
 Art: trained and experienced in painting, drawing, sculpting, and calligraphy; 
trained in poster and bulletin board making 
 Public speaking: Trained in public speaking (1 year), chosen high school 
commencement speaker 
 Emergency Response: AED, CPR, and First-Aid Certified by the American Red 
Cross 
 Microsoft Office: Strong knowledge of Microsoft Outlook, Excel, Word, Visio, 
and PowerPoint 
 Database and Program Knowledge: Experience working with JMP Pro 10, 
SPSS Statistical Software, and WordPress 
 
INTERESTS 
 Track and Field (varsity athlete in high school; events included the 100m hurdles, 
300m hurdles, triple jump, and high jump) 
 Distance running (ran the 2014 and 2015 Boston Athletic Association Half-
marathon, signed up to run the 2016) 
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 Swimming (swam club and at the varsity level for six years; events included the 
50m Freestyle, 100m Freestyle, and 100m Breaststroke) 
 General Fitness and Bodybuilding 
 Surfing and beach sports; held leadership roles in the renowned Huntington Beach 
Junior Lifeguard Program for eight years 
 Painting, drawing, and sculpting (work has been displayed in the Huntington 
Beach Art Center, Advanced Placement in high school; passed the national AP 
exam in visual arts) 
